Was the Corcept Therapeutics (CORT) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made under a Rule 10b5-1 trading plan adopted by Joseph K. Belanoff on November 26, 2024, and that the plan was in effect at the time of the sale.

What does the Form 4 say about the size of Corcept (CORT) CEO’s net share activity?

The Form 4 shows a net sale of 26,198 shares of common stock, all from a single open-market transaction. There were no reported option exercises, gifts, or tax-withholding events in this particular filing.

Corcept Therapeutics (CORT) CEO trust sells 26,198 company shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 26,198 shares of common stock at a weighted average price of $50.0735 per share. The trade was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.

The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust-related holdings reported for Belanoff total 2,918,326 shares of Corcept Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 26,198 shares ($1,311,826)

Net Sell 1 txn

Insider BELANOFF JOSEPH K

Role Chief Executive Officer

Sold 26,198 shs ($1.31M)

Type	Security	Shares	Price	Value
Sale	Common Stock	26,198	$50.0735	$1.31M

Holdings After Transaction: Common Stock — 2,918,326 shares (Indirect, Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELANOFF JOSEPH K

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/25/2026		S⁽¹⁾		26,198	D	$50.0735⁽²⁾	2,918,326	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Corcept Therapeutics (CORT) report for its CEO?

Corcept Therapeutics’ CEO Joseph K. Belanoff reported an indirect open-market sale of 26,198 common shares. The transaction was executed through a revocable living trust associated with him at a weighted average price of $50.0735 per share.

At what price did the Corcept Therapeutics (CORT) CEO’s trust sell shares?

The trust associated with Corcept’s CEO sold 26,198 shares at a weighted average price of $50.0735. Actual sale prices ranged from $50.00 to $50.32 per share, according to the disclosure’s detailed footnote.

How many Corcept Therapeutics (CORT) shares remain held after the CEO’s trust sale?

After selling 26,198 shares, the trust-related holdings reported for CEO Joseph K. Belanoff total 2,918,326 shares. This figure reflects indirect ownership through the revocable living trust identified in the filing.

How is the Corcept Therapeutics (CORT) CEO’s ownership described for this transaction?

The shares are held indirectly by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust. Belanoff has voting power via voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest in those shares.